📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Vijaya Diagnostic Q3 FY26: Record Revenue of ₹205 Cr, EBITDA Margins Expand to 41.9%
Vijaya Diagnostic reported its highest-ever quarterly revenue of ₹205 crores in Q3 FY26, marking a robust 21.4% YoY growth driven by a 14.7% increase in test volumes. Profitability showed significant improvement with EBITDA rising 28.2% YoY to ₹86 crores, while EBITDA margins expanded by 221 basis points to reach 41.9%. The company successfully expanded its footprint with four new hubs during the quarter, including two in West Bengal where early launches have already achieved breakeven within three quarters. Management maintains a strong balance sheet with a net surplus cash of ₹260 crores and has planned a capex of ₹100-120 crores for FY27 to fuel further expansion.
Key Highlights
Highest ever quarterly revenue of ₹205 crores, up 21.4% YoY with 14.7% volume growth
EBITDA margins expanded by 221 bps YoY to 41.9%, with PAT growing 22.3% to ₹43 crores
Core Hyderabad market grew 15% YoY, while West Bengal expansion showed early success with 3-quarter breakevens
Strong liquidity position with net surplus cash of ₹260 crores as of December 31, 2025
Planned FY27 capex of ₹100-120 crores focusing on 4-5 new hubs and 10-12 spokes
💼 Action for Investors
Investors should view the strong margin performance and rapid breakeven in new territories as a sign of efficient scaling. The stock remains attractive given its robust B2C mix and significant cash reserves for future growth.
Vijaya Diagnostic Appoints New CFO, COO, and CTO; Grants 1.15 Lakh ESOPs
Vijaya Diagnostic Centre has announced a major leadership restructuring, appointing Mr. Ankit Shah as the new Chief Financial Officer effective February 13, 2026. The company also strengthened its executive team by appointing Mr. Sai Prasad as CTO and Mr. Venkata Siva Rama Raju Vegesna as COO to drive digital and operational growth. Additionally, the board approved the grant of 1,15,000 ESOPs and the appointment of two new Independent Directors for five-year terms. The outgoing CFO, Mr. S. Ramachandra Reddy, will transition to a General Manager role within the finance department.
Key Highlights
Mr. Ankit Shah appointed as CFO, bringing 20+ years of experience in healthcare finance and M&A.
New CTO and COO roles filled to lead digital transformation and operational strategy.
Grant of 1,15,000 ESOPs approved under the VDCL Employee Stock Option Plan 2018.
Two Independent Directors appointed for 5-year terms, strengthening board governance.
Outgoing CFO Mr. S. Ramachandra Reddy remains with the company as GM - Finance & Accounts.
💼 Action for Investors
Investors should view this management refresh as a move toward professionalizing the leadership for the next phase of growth. Monitor the execution of digital initiatives under the new CTO and operational efficiencies under the new COO.
Vijaya Diagnostic Overhauls Leadership: Appoints New CFO, COO, and CTO
Vijaya Diagnostic Centre has announced a major leadership restructuring effective February 13, 2026, to strengthen its executive team. Mr. Ankit Shah, a Chartered Accountant with over 20 years of experience, has been appointed as the new CFO, replacing Mr. S. Ramachandra Reddy who transitions to a General Manager role. The company also appointed Mr. Venkata Siva Rama Raju Vegesna as COO and Mr. Sai Prasad as CTO to lead operations and digital transformation. Additionally, the board approved the grant of 1,15,000 ESOPs and inducted two new Independent Directors with legal and medical expertise.
Key Highlights
Appointment of Mr. Ankit Shah as CFO, bringing 20+ years of experience in healthcare finance and M&A.
Mr. Venkata Siva Rama Raju Vegesna joins as COO, previously serving as SVP Operations at KIMS Hospitals.
Mr. Sai Prasad appointed as CTO to drive large-scale digital transformation and IT strategy.
Grant of 1,15,000 Employee Stock Options (ESOPs) approved under the 2018 plan.
Induction of two new Independent Directors: Senior Advocate Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola.
💼 Action for Investors
Investors should view this professionalization of the C-suite as a positive step toward scaling operations. Monitor the new leadership's ability to execute growth strategies and integrate digital initiatives through the new CTO.
Vijaya Diagnostic Overhauls Leadership: Appoints New CFO, COO, CTO, and Two Directors
Vijaya Diagnostic Centre has announced a major management restructuring, appointing Ankit Shah as the new Chief Financial Officer, succeeding S. Ramachandra Reddy who transitions to a General Manager role. The company also strengthened its executive team by appointing Sai Prasad as Chief Technology Officer and Venkata Siva Rama Raju Vegesna as Chief Operating Officer. Furthermore, two Independent Directors with legal and medical expertise have been added to the board for five-year terms. To align interests, the board approved the grant of 1,15,000 ESOPs under the company's 2018 incentive plan.
Key Highlights
Ankit Shah appointed as CFO, bringing over 20 years of experience in healthcare finance and M&A.
Venkata Siva Rama Raju Vegesna returns to the company as COO after a stint at KIMS Hospitals.
Sai Prasad joins as CTO to lead digital transformation, previously serving as Director at UnitedHealth Group.
Board approved the grant of 1,15,000 ESOPs convertible into equity shares of face value ₹1 each.
Two new Independent Directors, Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, appointed for 5-year terms.
💼 Action for Investors
Investors should monitor how the new leadership team, particularly the new CFO and COO, impacts operational margins and expansion strategies. The return of a former strategy head as COO suggests a focus on scaling existing operations efficiently.
Vijaya Diagnostic Overhauls Leadership with New CFO, COO, and CTO; Grants 1.15 Lakh ESOPs
Vijaya Diagnostic Centre has announced a significant leadership restructuring, appointing Mr. Ankit Shah as the new CFO, replacing Mr. S. Ramachandra Reddy who will transition to a General Manager role. The company also strengthened its executive team by appointing Mr. Sai Prasad as CTO and Mr. Venkata Siva Rama Raju Vegesna as COO, both bringing extensive experience from the healthcare and technology sectors. Additionally, two new Independent Directors have been appointed for five-year terms, and the board approved the grant of 1,15,000 ESOPs to employees. These moves appear aimed at professionalizing management and driving digital and operational growth.
Key Highlights
Appointment of Mr. Ankit Shah as CFO, bringing 20+ years of experience in healthcare finance and M&A.
New CTO Mr. Sai Prasad and COO Mr. Venkata Siva Rama Raju Vegesna join to lead digital and operational strategies.
Grant of 1,15,000 Employee Stock Options (ESOPs) approved under the 2018 plan.
Two Independent Directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, appointed for 5-year terms.
Former CFO Mr. S. Ramachandra Reddy transitions to General Manager - Finance & Accounts to support the transition.
💼 Action for Investors
Investors should view the induction of experienced professionals from companies like UnitedHealth and KIMS as a positive step toward scaling operations. Monitor the impact of these new leaders on the company's digital transformation and margin efficiency in future earnings.
Vijaya Diagnostic Announces Major Management Overhaul and Grant of 1.15 Lakh ESOPs
Vijaya Diagnostic Centre has announced a significant leadership restructuring, including the appointment of a new CFO (Ankit Shah), COO (Venkata Siva Rama Raju Vegesna), and CTO (Sai Prasad). The board also approved the grant of 1,15,000 ESOPs under its 2018 plan, which are convertible into an equivalent number of equity shares. Alongside these executive changes, two new Independent Directors with legal and medical expertise have been appointed for five-year terms. These announcements were made following the board's approval of the Q3 and nine-month financial results for FY26.
Key Highlights
Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value each.
Appointment of Ankit Shah as Chief Financial Officer, succeeding S. Ramachandra Reddy who moves to a GM role.
Venkata Siva Rama Raju Vegesna appointed as COO, bringing experience from KIMS Hospitals and previous tenure at Vijaya.
Appointment of two new Independent Directors, Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.
New Chief Technology Officer (Sai Prasad) appointed to lead digital transformation and IT strategy.
💼 Action for Investors
Investors should monitor the impact of the new leadership team on the company's operational execution and strategic growth, while also reviewing the Q3 FY26 financial performance.
Vijaya Diagnostic Q3 Revenue Grows 21.4% to ₹2,052 Mn; EBITDA Margins Rise to 41.9%
Vijaya Diagnostic reported a strong Q3 FY26 with revenue growing 21.4% YoY to INR 2,052 Mn, driven by a 14.7% increase in test volumes. EBITDA margins expanded by 221 bps YoY to 41.9%, resulting in an EBITDA of INR 861 Mn. The company successfully commissioned four new hub centers during the quarter, expanding its footprint in West Bengal and its core markets. Net profit (PAT) rose 22.3% YoY to INR 432 Mn, maintaining a healthy 21% margin despite seasonal softness.
Key Highlights
Revenue from operations grew 21.4% YoY to INR 2,052 Mn in Q3 FY26
EBITDA increased by 28.2% YoY to INR 861 Mn, with margins improving to 41.9% from 39.7%
Test volumes rose 14.7% YoY to 4.22 Mn, while footfalls increased 11.8% to 1.17 Mn
Network expanded to 162 centers with 4 new hubs launched in West Bengal, Telangana, and Andhra Pradesh
B2C segment remains the core focus, contributing 92% of total revenue
💼 Action for Investors
Investors should favor the company's ability to maintain high margins while aggressively expanding into new geographies. The rapid break-even of new hubs in West Bengal suggests a highly scalable and efficient business model.
Vijaya Diagnostic Q3 FY26: Revenue Up 21.4% YoY, EBITDA Margins Expand to 41.9%
Vijaya Diagnostic reported a strong Q3 FY26 with revenue growing 21.4% YoY to ₹2,052.1 million, driven by a 14.7% increase in test volumes. Profitability improved significantly as EBITDA rose 28.2% YoY, leading to a margin expansion of 221 bps to 41.9%. The company successfully expanded its footprint in West Bengal and core markets, with new hubs breaking even faster than expected. Management's focus on high-end radiology and wellness (14.7% share) continues to drive realization per footfall higher by 8.6%.
Key Highlights
Revenue from operations grew 21.4% YoY to ₹2,052.1 Mn, surpassing Q2 levels despite seasonal softness.
EBITDA margins expanded by 221 bps YoY to 41.9%, while PAT increased 22.3% to ₹431.8 Mn.
Operational efficiency improved with average realization per footfall up 8.6% YoY to ₹1,756.
Rapid expansion in West Bengal with two hubs breaking even within 3 quarters, well ahead of the 1-year guidance.
Total test volume increased by 14.7% YoY to 4.22 million, supported by an 11.8% growth in footfall.
💼 Action for Investors
The company shows strong execution in non-core markets like West Bengal and maintains industry-leading margins. Investors should monitor the scalability of new hubs and the impact of the newly appointed leadership team on long-term growth.
Vijaya Diagnostic Announces Major Management Overhaul and Q3 FY26 Results Approval
Vijaya Diagnostic Centre has undergone a significant leadership restructuring, appointing a new CFO, CTO, and COO effective February 13, 2026. Mr. Ankit Shah succeeds Mr. S. Ramachandra Reddy as CFO, while the company also added two new Independent Directors to its board for five-year terms. The board approved the financial results for the quarter ended December 31, 2025, and authorized the grant of 1,15,000 ESOPs. Additionally, the company's Related Party Transaction policy was revised to enhance governance.
Key Highlights
Appointment of Mr. Ankit Shah as CFO and Mr. Venkata Siva Rama Raju Vegesna as COO.
Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value.
Appointment of two Independent Directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.
Mr. S. Ramachandra Reddy resigned as CFO to transition into a General Manager role within the company.
Approval of Unaudited Standalone and Consolidated Financial Results for Q3 and 9M ended December 31, 2025.
💼 Action for Investors
Investors should monitor the impact of the new leadership team on operational efficiency and review the detailed Q3 financial performance. The simultaneous change in CFO, COO, and CTO suggests a strategic organizational restructuring that warrants close observation.
Vijaya Diagnostic Announces Major C-Suite Overhaul; Appoints New CFO, COO, and CTO
Vijaya Diagnostic Centre has announced a significant leadership restructuring, appointing Ankit Shah as the new Chief Financial Officer following the resignation of S. Ramachandra Reddy. The company also strengthened its executive team by appointing Sai Prasad as CTO and Venkata Siva Rama Raju Vegesna as COO, the latter returning from KIMS Hospitals. Additionally, the board approved the grant of 1,15,000 ESOPs to employees and inducted two new Independent Directors with legal and medical expertise. These changes appear aimed at modernizing operations and scaling the business through specialized leadership.
Key Highlights
Appointment of Ankit Shah as CFO, a Chartered Accountant with 20+ years of experience in healthcare finance.
Venkata Siva Rama Raju Vegesna appointed as COO, bringing back expertise from his previous tenure at Vijaya and KIMS Hospitals.
Grant of 1,15,000 Employee Stock Options (ESOPs) convertible into equity shares of ₹1 face value.
Appointment of Sai Prasad as CTO to lead digital transformation, previously Director at UnitedHealth Group.
Induction of two Independent Directors, Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola, for 5-year terms.
💼 Action for Investors
Investors should view the infusion of high-caliber talent in technology and operations as a positive step toward scaling; however, watch for the execution of the new CFO's financial strategies in upcoming quarters.
Vijaya Diagnostic Allots 1.71 Lakh Shares Following Medinova Amalgamation
Vijaya Diagnostic Centre Limited has completed the allotment of 1,71,792 equity shares to the shareholders of Medinova Diagnostic Services Limited. This procedural step follows the NCLT-approved Scheme of Amalgamation, with the record date previously fixed as November 25, 2025. Consequently, the company's paid-up equity share capital has increased from approximately ₹10.27 crore to ₹10.29 crore. Fractional entitlements will be managed by an independent trustee, who will sell the consolidated shares and distribute the proceeds to eligible shareholders.
Key Highlights
Allotment of 1,71,792 equity shares of face value ₹1 each to Medinova shareholders.
Total paid-up equity share capital increased from ₹10,26,87,111 to ₹10,28,96,728.
The allotment is pursuant to the NCLT Hyderabad Bench order dated October 13, 2025.
Fractional entitlements consolidated and allotted to Catalyst Trusteeship Limited for open market disposal.
Shares will rank pari-passu with existing equity and will be listed on both NSE and BSE.
💼 Action for Investors
This is a routine procedural update following a previously announced merger; investors should note the minor equity dilution which is unlikely to impact the stock price significantly. No immediate action is required as the integration process is nearing completion.